<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment of patients suffering from <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is often unsuccessful </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="180" ids="32871">Pro-</z:chebi><z:mpath ids='MPATH_3'>apoptosis</z:mpath> with <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi> has recently been proposed as a novel therapeutic approach </plain></SENT>
<SENT sid="2" pm="."><plain>Exisulind is another potentially pro-apoptotic agent, and therefore, we investigated its influence on proliferation, differentiation, cell cycle and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in two sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cell lines, one de-novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell line and healthy CD34+ bone marrow cells </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment of sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells with Exisulind clearly inhibited colony formation in the CFU-assays </plain></SENT>
<SENT sid="4" pm="."><plain>Interestingly, Exisulind did not alter the percentages of sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells in G1-, G2-, M- or S-phase, but reduced proliferation and induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in this cell type </plain></SENT>
<SENT sid="5" pm="."><plain>Exisulind had no effect on de-novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:mpath ids='MPATH_458'>normal</z:mpath> CD34+ cells </plain></SENT>
<SENT sid="6" pm="."><plain>We detected increased c-Jun <z:chebi fb="0" ids="29318,29339">NH2</z:chebi>-terminal kinase activity in sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells treated with Exisulind </plain></SENT>
<SENT sid="7" pm="."><plain>Adding a specific JNK-inhibitor to Exisulind-treated sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells partly abrogated <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, thus proving that Exisulind-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells is dependent on JNK activation </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that JNK is one mediator of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells treated with Exisulind </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, our data strongly suggests to explore the potential use of Exisulind as a novel, pro-apoptotic therapy for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>